Skip to main content
Premium Trial:

Request an Annual Quote

MRC Holland SALSA Digital MLPA Probemixes for Multiple Myeloma and Acute Lymphoblastic Leukemia

MRC Holland has launched two new research-use-only assays for hematological malignancies: SALSA Digital MLPA Probemix D006 Multiple Myeloma and SALSA DigitalMLPA Probemix D007 Acute Lymphoblastic Leukemia.

The multiple myeloma panel targets all non-acrocentric chromosomal arms to enable the detection of large copy number alterations and ploidy changes. Chromosomal regions that are frequently altered in multiple myeloma, including 1q, 1p, 13q, and 17p, are especially well-covered, allowing for high-resolution screening of these arms. The assay also covers genes of emerging significance, such as BCMA and GPRC5D, MRC Holland said.

The ALL assay includes all the targets from ALL-relevant SALSA MLPA probemixes and more in one assay. A single reaction is enough to simultaneously screen for numerous ALL-related alterations, such as intragenic copy number alterations (e.g. IKZF1del), aneuploidies (e.g. 5q deletion), whole chromosome gains, losses and amplifications (e.g. iAMP21), gross ploidy changes (e.g. high hyperdiploidy), and intrachromosomal gene fusions (e.g. STIL-TAL1 fusion), the company said. In addition, this panel includes probes that target subtelomeric, pericentromeric, and middle regions of most chromosomal arms. This allows the detection of larger copy number alterations and ploidy status (hyperdiploidy and hypodiploidy).

Both panels are based on MRC Holland's SALSA DigitalMLPA technology, which merges the MLPA method with next-generation sequencing. Both assays are available worldwide, a company spokesperson said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.